Yahoo
BSE - Delayed Quote INR

Cipla Limited (CIPLA.BO)

1,380.00 +23.00 (+1.69%)
At close: October 30 at 3:51:06 PM GMT+5:30
Chart Range Bar
Loading chart for CIPLA.BO
  • Previous Close 1,357.00
  • Open 1,368.95
  • Bid 1,373.70 x --
  • Ask 1,380.00 x --
  • Day's Range 1,360.60 - 1,381.25
  • 52 Week Range 1,283.00 - 1,672.20
  • Volume 25,228
  • Avg. Volume 121,684
  • Market Cap (intraday) 1.115T
  • Beta (5Y Monthly) -0.05
  • PE Ratio (TTM) 24.56
  • EPS (TTM) 56.20
  • Earnings Date (est.) Jan 21, 2027
  • Forward Dividend & Yield 13.00 (0.98%)
  • Ex-Dividend Date Jun 27, 2025
  • 1y Target Est 1,458.53

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

www.cipla.com

30,313

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 70.74B
Earnings 6.76B
Profit Margin 9.55%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
20B
40B
60B
10.0%
12.0%
14.0%
16.0%
18.0%

Analyst Insights

View More

Analyst Price Targets

1,170.00 Low
1,458.53 Average
1,380.00 Current
1,827.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    16.26%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    279.67B

  • Net Income Avi to Common (ttm)

    45.46B

  • Diluted EPS (ttm)

    56.20

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    106.02B

  • Total Debt/Equity (mrq)

    1.41%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: